FUS and sarcoma: To determine whether LMNs with ALS mutations exhibit pathological phenotypes, we used four ALS-iPSC lines carrying genetic mutations in either TDP-43 (TARDBP, TAR DNA binding protein 43) or FUS (fused in sarcoma).